Related Experiment Video
Updated: Apr 30, 2026
06:00
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
6.6K
Everolimus.
1Department Innere Medizin, Klinik für Innere Medizin I, Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation, Hugstetter Str. 55, 79102, Freiburg, Germany, jens.hasskarl@uniklinik-freiburg.de.
Summary
Everolimus is an oral mTOR inhibitor approved for advanced cancers like renal cell carcinoma and breast cancer. Ongoing trials explore its broader role in oncology, targeting cell growth and proliferation pathways.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- The mammalian target of rapamycin (mTOR) pathway is crucial for cell growth and proliferation.
- Deregulation of the mTOR pathway is common in various cancers.
- Everolimus is an oral mTOR inhibitor targeting this pathway.
Purpose of the Study:
- To summarize the approved indications and ongoing research for everolimus in oncology.
- To highlight the role of mTOR inhibition in cancer treatment.
Main Methods:
- Review of FDA and EMA approved indications for everolimus.
- Summary of ongoing phase 2 and phase 3 clinical trials.
- Focus on everolimus's mechanism as a protein kinase inhibitor.
Main Results:
- Everolimus is approved for advanced renal cell carcinoma, tuberous sclerosis-associated SEGA, pancreatic neuroendocrine tumors, and HR+/HER2- breast cancer.
- The drug demonstrates promising clinical activity in other cancer types.
- Multiple trials are investigating everolimus's efficacy alone and in combination therapies.
Conclusions:
- Everolimus is an established mTOR inhibitor with significant applications in oncology.
- Further clinical trials are essential to fully understand its therapeutic potential in various cancers.
- The mTOR pathway remains a key target for cancer therapy development.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
414
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
414
01:28Renal Drug Excretion: Tubular Secretion
1.2K
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
1.2K
01:13Bioequivalence studies: Biowaivers
430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
01:15Drug Elimination by Renal Route: Tubular Secretion
3.4K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
3.4K
01:22Drug Elimination by Renal Route: Tubular Reabsorption
4.6K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
4.6K